Prescribing information

 

   

For patients on ICS monotherapy, ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder) a long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) (IND/MF) is available in three different doses: low, medium and high.*1

Atectura device with icon of 1 times daily

ATECTURA® BREEZHALER®

LABA/ICS available with 3 different ICS doses:*1

• Low-dose: ATECTURA® BREEZHALER® 125/62.5 μg (once-daily)

• Medium-dose: ATECTURA® BREEZHALER® 125/127.5 μg (once-daily)

• High-dose: ATECTURA® BREEZHALER® 125/260 μg (once-daily)

With the flexibility to adjust ICS dose as needed

 

Confirmed dose – See that the full dose has been taken1

Correct use – Low rate of critical errors*†2

Comfortable inhalation – Low airflow resistance*‡3

 

 

 

 

 

50%

of patients are unable to use their inhaler properly, even with training§4

 

How to use the BREEZHALER® device

Watch the following video to learn how to use the BREEZHALER®.

 

 

*Contained doses: ATECTURA® BREEZHALER® low dose = IND/MF 150/80 μg (once daily); ATECTURA® BREEZHALER® medium dose = IND/MF 150/160 μg (once daily); ATECTURA® BREEZHALER® high dose = IND/MF 150/320 μg (once daily).
In a study where 262 healthcare professionals assessed the handling of 3,393 devices used for continuous treatment of COPD in 2,935 patients. Devices assessed were BREEZHALER® (n=876), Diskus® (n=452), Handihaler® (n=598), Pressurised metered-dose inhaler (pMDI) (n=422), Respimat® (n=625) and Turbuhaler® (n=420).2
Compared to Ellipta® and HandiHaler®.3
§96 pharmacies collected data from 570 adult asthma patients in Australia. Of these, 348 patients were taking preventer/combination medication on a regular basis and were included. All patients who demonstrated incorrect technique at Visit 1 were trained to mastery. Of these, data was available for 238 at follow-up visit.4

Indication: ATECTURA® BREEZHALER® is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.1

ICS, inhaled corticosteroids; IND, indacaterol; LABA, long-acting beta-agonist; MF, mometasone furoate.

Reference

  1. ATECTURA® BREEZHALER® Summary of Product Characteristics.
  2. Molimard M et al. Eur Respir J 2017;49:1601794.
  3. Altman P et al. BMC Pulm Med 2018;18:100.
  4. Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
Rate this content: 
No votes yet
UK | March 2021 | 103415
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]